Post on 31-Jan-2022
transcript
INVESTOR OVERVIEW
NASDAQ: SRTS
February 2020
SRT-100 Vision
Investor Overview
NASDAQ: SRTS
December 2020
Forward-Looking Statements
This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these
forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,”
“potential” or, in each case, their negative or other variations thereon or comparable terminology, although not all
forward-looking statements contain these words.
By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive
dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may
or may not occur in the future or may occur on longer or shorter timelines than anticipated, including the continuation
and severity of the COVID-19 pandemic and its impact on sales and marketing. Although we believe that we have a
reasonable basis for each forward-looking statement contained in this presentation, we caution you that forward-looking
statements are not guarantees of future performance and that our actual results of operations, financial condition and
liquidity, and the development of the industry in which we operate may differ materially from the forward looking
statements contained in this presentation, as a result of, among others, the factors described from time to time in
Sensus Healthcare’s filings with the Securities and Exchange Commission.
In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in
which we operate are consistent with the forward-looking statements contained in this presentation, they may not be
predictive of results or developments in future periods. Any forward-looking statements that we make in this presentation
speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events
or circumstances after the date of this presentation. You should read carefully our “Cautionary Note Regarding Forward-
Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the
Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Safe Harbor Statement
PAGE 2
▪ Large U.S. market for Superficial Radiation Therapy (SRT) with OUS and
pipeline opportunities
▪ SRT systems allow practitioners an ROI in as little as 6-9 months, with 66%
increased reimbursement for main SRT code to improve ROI (01/02/2021)
▪ Introduced Sentinel™ - a powerful I.T. platform that provides Sensus with
opportunity for shared revenue
▪ Purchased two aesthetic mobile laser companies in Florida
▪ Provides $1 million additional annual revenue and opportunity to leverage
customer base and add in proprietary lasers
▪ Proven ability to achieve profitability, with net income of $1.0 million in 4Q
2019, and expectations to resume profitability after COVID-19 pandemic
eases
▪ Strong balance sheet with $15.5 million in cash and equivalents, and no
long-term debt at Sept. 30, 2020, supported by careful attention to expenses
▪ Executive team has extensive record with capital equipment models
▪ Sculptura™ - Anisotropic Radiation Therapy (ART) with Beam
Sculpting™ capabilities / Robotic Respiratory Tracking for multiple
indications
Investment Highlights
PAGE 4
SRT-100+™
SRT-100 Vision™
▪ Low-energy Photon Radiotherapy
⮚ 100% of the energy is focused directly on surface
of skin using customized proprietary applicators
⮚ Penetrates no deeper than 5mm below skin’s surface
⮚ Covered by IP portfolio
▪ Scalable platform – new future indications, such
as psoriasis
▪ Sentinel multi-featured, state-of-the-art cloud
platform
Core Technology - SRT
PAGE 7
SRT-100 Vision™
▪ A keloid is an area of irregular fibrous tissue formed at the site of a scar or injury*
Treatment Challenges
▪ Surgery and other current treatment methods are not a permanent solution▪ Recurrence rates of keloids are up to 80%▪ Expensive treatments are usually paid out-of-pocket by the patient ▪ Insurance covers treatment only if combined with SRT▪ Sensus is the only FDA cleared system to treat keloids
*Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225895/Journal of Family Practice (May 2013); Keloids: Which treatment is best for your patient?
What are Keloids?
PAGE 12
Skin Cancer:
▪ Clinical multi-center study in 2019 of 776 lesions, 5 yr. retrospective study – 98.9%
cure rate
▪ Clinical study of 151 lesions on lower extremities in 2018, 97.35% cure rate and 5-year
success rate of 97%
▪ Cognetta et al (2012) retrospective analysis on 1,715 confirmed primary cutaneous
basal cell carcinoma (“BCC”) and squamous cell carcinoma (“SCC”) treated with SRT
between 2000 and 2010; 5 year recurrence rate 5%
Keloids:
▪ Clinical study in 2018 on keloid surgery followed with SRT for 297 lesions had 97%
success rate
▪ Dr. Michael Jones; Long term clinical study with 48 subjects followed over the course
of 12 months to monitor outcomes; 94% success rate
▪ Prospective study in Journal of Clinical and Aesthetic Dermatology showed Kaplan-
Meier cure rate of 85.6% from 24 months post-SRT treatment
Clinical Studies
PAGE 14
Unique, image-guided therapy: “See & treat”
▪ World’s first designed to:
⮚ Track disease progression
⮚ Plan treatment
⮚ Guide therapy
⮚ Administer radiation
⮚ Evaluate treatment
⮚ Ultrasound capabilities
The SRT-100 Vision
PAGE 16
SLAS created by the acquisitions of Aesthetic Mobile Laser
Services and Aesthetic Laser Partners, with 30 lasers and six vans
▪ Brings to Sensus:
⮚ $1.0+ million in revenues over the next 12 months (assumes dermatology
clinics will be at 80% of their pre-COVID-19 patient levels)
⮚ Immediate earnings accretion
⮚ Full Florida coverage with150 - 200 dermatology practices
⮚ 500+ potential new customers for Sensus’ existing SRT products
⮚ Recurring revenue model via mobile laser rentals
⮚ Addition of proprietary aesthetic lasers equipped with Sentinel (FDA
clearance expected by year-end 2020
▪ Supports shared service models
▪ Permits direct patient billing
Sensus Laser Aesthetic Solutions
PAGE 19
State-of-the-art Anisotropic Radiation Therapy device
Sculptura System
PAGE 21
⮚ Robotic respiratory motion tracking
⮚ Beam Sculpting™
⮚ Photon radiotherapy
⮚ Tomosynthesis imaging
• Ocular
• Glioblastoma
Head & Neck
• Breast
• Recurrent Breast
Breast
• Pancreatic
Pancreas
• Vaginal
• Cervical
• Ovarian
OBGYN
• Colorectal
• Stomach
• GI Tract
GI/Colorectal
• Recurrent abdomino-pelvic tumors
Pelvic
• Liver
• Bladder
Hepatobiliary
• Lung
• Thoracic
Thoracic & Lung
• Spine
• P32 plaques
CNS
• Prostate
Prostate
Pediatrics• Intra-abdominal
• Recurrent disease
Source: Dr. Neil Taunk, Penn Medicine - GLCOE
Sa
rco
ma
(soft tissu
e tru
nk
an
d e
xtre
mity
)
Sculptura Target Indications
PAGE 22
Sculptura Positioning
PAGE 23
▪ List price of $1.5 million, compared with $xxx for
competing systems
▪ Expected high-margin; consumables provide
recurring revenues
▪ Strategic rollout to university hospital centers to
support research studies for marketing use and
provide wider validation – UPENN, Rabin Medical
Center, Stanford University
▪ Established reimbursement; 8,300 potential U.S.
sites plus 8,000 international market
▪ Single, targeted dose of radiation; no need for
course of radiation treatments
⮚ Provides savings to the healthcare system
⮚ Provides better patient care; less radiation with
similar outcomes
⮚ Ease of mobility between treatment rooms
Compelling solution for Sensus, patients, physicians,
hospitals and payors
PAGE 24
Sentinel IT Solution
Features- Data and cloud storage
- Remote diagnostics
- HIPPA compliant billing
- iOS compatible
Introducing our state-of-the-art cloud platform. Sentinel is installed directly onto the SRT-100 Vision, or
Sculptura device.
▪ One-time sale of capital equipment with annual service contract
⮚ Sentinel™ software provides capability for recurring/shared revenue
programs
▪ Recurring revenue from service contracts – 34% of installed base
under service contracts
▪ Recurring revenue from SLAS
▪ Sculptura provides both one-time equipment sales revenue and
attractive recurring revenue from disposables
▪ Investing in sales and marketing
▪ Investing in direct-to-consumer programs in conjunction with
physicians,
▪ Raising awareness of SRT treatment for keloids
▪ Goal is profitability for 2021 leveraging past R&D investments
Our Financial Model
PAGE 25
▪ The lights went out as the country shut down in March 2020 to combat
COVID-19
⮚ As a result the momentum Sensus experienced in 4Q19 abruptly halted
▪ Sensus used the shutdown to keep in front of its customers, providing
PPE, and sponsoring Zoom seminars for physicians to help them navigate
the new rules for their practices
▪ SRT came to forefront in the armamentarium for non-melanoma skin
cancer, especially in the COVID-19 environment, with increased utilization
− even by Mohs surgeons
COVID-19 Impact & Reopening Plan
PAGE 26
▪ The lights are slowly and cautiously coming on now with many
states easing public health restrictions
⮚ Our sales reps are able to see new and existing customers!
▪ Following safe guidelines we expect to regain momentum with
improvement in Q4/20
▪ With increased reimbursement for SRT, we expect a resumption in
growth and sustained profitability in 2021
Management TeamJoseph C. Sardano, Founder, President & CEO
▪ Elscint Medical Imaging – Vice President driving Sales & Marketing, led to
joint acquisition between General Electric and Picker Medical (Philips)
Imaging totaling approximately $650M.
▪ GE Healthcare – GSM, Functional Imaging (Positron Emission Tomography)
imaging group, capturing #1 market share as well as reaching $320 million
in sales within the first 24 months.
▪ CTI Molecular Imaging/Siemens Medical Imaging – Sr. Vice President,
Molecular Imaging. Built top caliber team capturing 35% market share in one
year. Accelerated put-call option with Siemens resulting in an acquisition
valued at $2.2 billion.
Steve Cohen, Co-Founder and EVP of Strategic
Initiatives & Dermatology▪ Technicare (J&J) – Regional Sales Manager
▪ Don L Leasing – CEO
▪ Xoft – Regional Sales Manager
▪ Diasonics – Regional Sales Manager
Javier Rampolla, CFO▪ 20+ years of financial experience
▪ QEP – Director of Accounting
▪ Stanley Black & Decker – Asst.
controller for Latin America
Russ Price, CTO▪ 20+ years of experience in
PET/Molecular Imaging
▪ RbM Services – Product Manager
▪ Advanced Biomarker Technologies
– Contract Project Engineer
Nicolas Soro, COO
▪ Sensus Healthcare – Director of
Regulatory Affairs and Quality Assurance
▪ DemeTECH Corporation – Director of
Regulatory Affairs and Quality Assurance
▪ DemeTECH Corporation – Network
Administrator
Hoi-Bun “Benson” Suen, VP
of International Sales▪ 20+ years of bus. dev., sales &
regulatory experience
▪ Director, Bus.Dev. Fosun Pharma
▪ Sr. Mgr, Bus. Dev & Regulatory at
Chindex International
Michael Sardano, VP &
General Counsel• Sensus Healthcare – State & Federal
Regulatory Matters, Government
Affairs, & SEC Compliance
• Served on the United States Senate
Rules & Administration Committee
• Licensed State Attorney
PAGE 27
Paul Miano, VP of SLAS• Founder Aesthetic Mobile Laser
Services
• 21+ years of operational and services
experience
• Built Aesthetic Mobile Laser Services
into leader in Southeast and Southwest
Florida
✔ Disruptive patented technology adaptable to other skin
conditions and other cancers
✔ Large, growing, underserved market
✔ Significant advantage to patients compared to existing
treatments
✔ Improved physician productivity and economics
✔ Technology transitions well into the new healthcare
system: high efficacy and cost effective
✔ Sculptura™ provides an additional avenue for high-
margin growth
SRT-100 Vision™
Summary
PAGE 28